Biotin Anti-Mouse CD274 (PD-L1) Antibody

Product Details


Clone10F.9G2
ApplicationFlow Cytometry
ReactivityMouse
FormatBiotin
Target NameCD274, PD-L1, B7-H1
IsotypeRat IgG2b
Antibody TypeMonoclonal
Regulatory StatusRUO
FormulationPhosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA
Protein Concentration0.2 mg/mL
Storage and HandlingThe antibody solution should be stored between 2°C and 8°C
Recommended UsageFor flow cytometric staining, it is recommended to use less than 0.1 µg of this reagent per 0.5-1.0 million cells in a 100 µL volume. Optimal reagent performance should be determined by titration for each specific application. For detection, use a secondary reagent with this product.
RRIDAB_3739038
Research AreasActivated T cells, Activated B cells, Monocytes, Macrophages, Dendritic cells, NK cells, Immune Checkpoints, Cancer Immunology
See All FormatsClone 10F.9G2

Background Information


Programmed death-ligand 1 (PD-L1), also known as CD274 or B7-H1, is a transmembrane protein that plays a pivotal role in immune regulation by modulating T cell activity. PD-L1 is expressed on a wide range of cells, including antigen-presenting cells, epithelial cells, and many tumor cells. Its primary function is to bind to its receptor, programmed cell death protein 1 (PD-1), located on activated T cells. This interaction delivers an inhibitory signal that reduces T cell proliferation, cytokine production, and cytotoxicity, thereby maintaining immune homeostasis and preventing autoimmunity. However, in pathological contexts such as cancer, PD-L1 expression allows tumor cells to evade immune attack, creating an immunosuppressive microenvironment.

Structurally, PD-L1 is a type I transmembrane glycoprotein belonging to the B7 family of immune checkpoint molecules. The extracellular domain comprises two immunoglobulin-like regions—an IgV-like domain responsible for PD-1 binding and an IgC-like domain that stabilizes the molecule. The protein also contains a single transmembrane helix and a short cytoplasmic tail that lacks classical signaling motifs but may interact with intracellular partners influencing its stability and localization. The PD-L1–PD-1 complex adopts a well-characterized interface where the IgV domains of both molecules interact in a way that blocks T cell receptor-mediated activation signaling.

The main ligands of PD-L1 are PD-1 and CD80 (B7-1). While PD-1 engagement results in T cell inhibition, interaction with CD80 may yield bidirectional signaling effects depending on the cellular context. PD-L1 can be induced by inflammatory cytokines such as interferon-gamma (IFN-γ), linking innate immune responses to immune checkpoint modulation.

PD-L1 plays a major role in numerous diseases. Overexpression of PD-L1 is a hallmark of many cancers, including lung, melanoma, renal, and breast cancers, where it contributes to immune escape. Therapeutically, blocking the PD-1/PD-L1 axis with immune checkpoint inhibitors has revolutionized cancer treatment. Drugs such as pembrolizumab, nivolumab, and atezolizumab disrupt this inhibitory pathway, restoring antitumor T cell function. Moreover, PD-L1 is being explored as both a predictive biomarker for immunotherapy response and a target for novel therapies, including bispecific antibodies and CAR-T cells aimed at enhancing immune-mediated tumor clearance.

Isotype Control


Biotin Rat IgG2b Isotype Control Antibody

Data Sheets


Biotin Anti-Mouse CD274 (PD-L1) Antibody TDS

Related Protocols


Flow Cytometry Protocol

Related Products


Anti-Human PD1 (Nivolumab Biosimilar), Clone Nivolumab

Anti-Human PD1 (Pembrolizumab Biosimilar), Clone Pembrolizumab

Biotin Human PD-L1 (CD274) Protein (C-His-Avi)

Anti-Human PD-L1 (Atezolizumab Biosimilar), Clone Atezolizuma

PE Human PD-L1 (CD274) Protein (C-His)

In Vivo Star Anti-Mouse CD274 (PD-L1) Antibody, Clone 10F.9G2-m2aSL

In Vivo Star Anti-Mouse CD274 (PD-L1) / CD279 (PD1) Bispecific Antibody, Clone 10F.9G2 / RMP1-14

In Vivo Star Anti-Mouse CD370 / CD274 (PD-L1) Bispecific Antibody, Clone 10B4 / 10F.9G2

In Vivo Star Anti-Mouse CD274 (PD-L1) / VEGF-A Bispecific Antibody, Clone 10F.9G2 / B20-4.1.1

In Vivo Star Anti-Mouse CD274 (PD-L1) / VEGF-A Bispecific Antibody, Clone 10F.9G2.1 / G6-23

Frequently Asked Questions


How do I determine the optimal antibody concentration/titer for my experiment?
We recommend titrating each new antibody lot on your own cell type and instrument, since optimal concentration depends on cell density, target expression level, and cytometer sensitivity. Suggested starting dilutions or test sizes (e.g., µg or µl per 10^6 cells) are provided on the product page as a starting reference point, not a fixed requirement.

Can these antibodies be used for intracellular or intranuclear staining, or only surface staining?
Intended use (surface, intracellular, or both) is specified per product, indicated under Application. The appropriate Related Protocol is linked for each product. If you need to detect both surface and intracellular markers in the same panel, confirm each antibody's compatibility with your fixation/permeabilization protocol before combining them.

What controls should I use alongside these antibodies?
Matched isotype controls (same host species, isotype, and conjugate) are available for most clones to help distinguish specific binding from background/non-specific staining and are linked on each product page. Unstained, single-color compensation, and fluorescence-minus-one (FMO) controls are also recommended, especially for multicolor panel design.

Can I combine InnoCyto Flow Cytometry antibodies into a multicolor panel?
Yes — antibodies across our catalog are designed to be panel-compatible, and conjugate options are offered specifically to support multiplexing. When building a panel, pair bright fluorophores with low-expression targets, avoid excessive spectral overlap, and confirm compensation is set up correctly for your specific fluorochrome combination. Use our Panel Builder to simplify the process.

Have a product or application question? Consult our FAQs or contact us.